Boscarino Joseph A, Hoffman Stuart N, Han John J
Center for Health Research, Geisinger Clinic, Danville, PA, USA.
Department of Pain Medicine, Geisinger Clinic, Danville, PA, USA.
Subst Abuse Rehabil. 2015 Aug 19;6:83-91. doi: 10.2147/SAR.S85667. eCollection 2015.
Previously, we estimated the prevalence and risk factors for prescription opioid-use disorder among outpatients on opioid therapy using the Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 and DSM-4 criteria. However, at the time, the DSM-5 criteria were not finalized. In the current study, we analyzed these data using the final DSM-5 criteria and compared these results.
Using electronic records from a large US health care system, we identified outpatients receiving five or more prescription orders for opioid therapy in the past 12 months for noncancer pain (mean prescription orders =10.72; standard deviation =4.96). In 2008, we completed diagnostic interviews with 705 of these patients using the DSM-4 criteria. In the current study, we reassessed these results using the final DSM-5 criteria.
The lifetime prevalence of DSM-5 opioid-use disorders using the final DSM-5 criteria was 58.7% for no or few symptoms (<2), 28.1% for mild symptoms (2-3), 9.7% for moderate symptoms (4-5), and 3.5% for severe symptoms (six or more). Thus, the lifetime prevalence of "any" prescription opioid-use disorder in this cohort was 41.3% (95% confidence interval [CI] =37.6-45.0). A comparison to the DSM-4 criteria indicated that the majority of patients with lifetime DSM-4 opioid dependence were now classified as having mild opioid-use disorder, based on the DSM-5 criteria (53.6%; 95% CI =44.1-62.8). In ordinal logistic regression predicting no/few, mild, moderate, and severe opioid-use disorder, the best predictors were age <65 years, current pain impairment, trouble sleeping, suicidal thoughts, anxiety disorders, illicit drug use, and history of substance abuse treatment.
Given the final DSM-5 criteria, including the elimination of tolerance and withdrawal, inclusion of craving and abuse symptoms, and introduction of a new graded severity classification, the prevalence of opioid-use disorders has changed, while many of the DSM-4 risk factors for opioid dependence were similar. To our knowledge, this is one of the first studies to compare the final results for DSM-5 versus DSM-4 prescription opioid-use disorders among a high-risk patient population.
此前,我们使用《精神疾病诊断与统计手册》(DSM)-5和DSM-4标准评估了接受阿片类药物治疗的门诊患者中处方阿片类药物使用障碍的患病率及风险因素。然而,当时DSM-5标准尚未最终确定。在本研究中,我们使用最终的DSM-5标准分析了这些数据并比较了结果。
利用美国一个大型医疗保健系统的电子记录,我们确定了在过去12个月中因非癌性疼痛接受5次或更多次阿片类药物治疗处方的门诊患者(平均处方次数=10.72;标准差=4.96)。2008年,我们使用DSM-4标准对其中705名患者进行了诊断访谈。在本研究中,我们使用最终的DSM-5标准重新评估了这些结果。
根据最终的DSM-5标准,DSM-5阿片类药物使用障碍的终生患病率为:无症状或症状轻微(<2项)的为58.7%,轻度症状(2 - 3项)的为28.1%,中度症状(4 - 5项)的为9.7%,重度症状(6项或更多)的为3.5%。因此,该队列中“任何”处方阿片类药物使用障碍的终生患病率为41.3%(95%置信区间[CI]=37.6 - 45.0)。与DSM-4标准相比,根据DSM-5标准,大多数终生患有DSM-4阿片类药物依赖的患者现在被归类为患有轻度阿片类药物使用障碍(53.6%;95%CI =44.1 - 62.8)。在预测无/轻微、轻度、中度和重度阿片类药物使用障碍的有序逻辑回归分析中,最佳预测因素为年龄<65岁、当前疼痛损伤、睡眠障碍、自杀念头、焦虑症、非法药物使用以及药物滥用治疗史。
鉴于最终的DSM-5标准,包括取消耐受性和戒断症状、纳入渴望和滥用症状以及引入新的分级严重程度分类,阿片类药物使用障碍的患病率发生了变化,而许多DSM-4中阿片类药物依赖的风险因素是相似的。据我们所知,这是首批在高危患者群体中比较DSM-5与DSM-4处方阿片类药物使用障碍最终结果的研究之一。